Hormonal
GLP-1 receptor agonists (GLP-1RAs) provide cardiovascular protection by reducing systemic inflammation, improving endothelial function, and reducing epicardial adipose tissue (EAT) volume, independent of weight loss.
If you have Type 2 Diabetes or Obesity, GLP-1 receptor agonists (like Ozempic, Wegovy, or Victoza) offer heart protection beyond just weight loss. They reduce inflammation in your blood vessels and shrink fat around your heart (EAT), which lowers your risk of heart disease. This benefit happens even if you don't lose a huge amount of weight. Talk to your doctor about whether these medications are right for your cardiovascular health.
GLP-1RAs have shown several potential cardiovascular benefits beyond glycemic control... Anti-atherosclerotic effects were supported through reduced carotid intima-media thickness... Liraglutide treatment... led to a rapid and significant 20% reduction in EAT thickness, measured by ultrasound, independently of overall weight loss, suggesting a direct, cardioprotective effect of liraglutide on EAT beyond glucose control.
Why this rating
Supported by multiple meta-analyses, RCTs, and mechanistic studies cited in the review.
Source
Role of endogenous incretin hormones, GLP-1 and GIP, in cardiovascular physiology
Kovid Trivedi et al. · Canadian Journal of Physiology and Pharmacology · 2026
DOI 10.1139/cjpp-2025-0163
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →